| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$266 |
Completion of Institutional Component of Equity Raising
|
27 Feb 2026 9:52AM |
$1.715 |
$0.395 |
fallen by
76.97%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful completion of the institutional component of equity raising
- Total expected to raise approximately $200 million
- Institutional Entitlement Offer raised approximately $157 million
- Retail Entitlement Offer expected to raise a further $43 million
- New Shares to trade on the ASX from 6 March 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Humm Group Limited (HUM) ORDINARY FULLY PAID |
Financials |
$323 |
TOV: HUM - Panel Accepts Undertaking Continues Proceedings
|
27 Feb 2026 9:52AM |
$0.665 |
$0.645 |
fallen by
3.01%
|
|
HUM - Price-sensitive ASX Announcement
Full Release
Key Points
- Humm Group Limited was involved in proceedings with the Australian Takeovers Panel concerning insider participation and conflicts of interest.
- The Panel accepted an undertaking from Humm which addressed these issues by forming an Independent Board Committee (IBC) excluding conflicted members.
- The undertaking requires Humm to appoint and include non-conflicted non-executive directors in the IBC to handle the Credit Corp Proposal.
- The CEO of Humm is to be appointed to the board as part of the undertaking.
- Humm is tasked with finding a new independent non-executive director to chair the IBC.
- Credit Corp Proposal involves acquiring control over Humm with conditions that raised concerns about conflicts of interest involving Mr. Abercrombie.
- No non-disclosure agreement had been signed with Credit Corp by February 2026, leading to ongoing procedural issues.
- The Panel emphasized that complex issues like insider participation require careful handling, focusing on substance over form.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID |
Health Care |
$1,080 |
Half Year Accounts
|
27 Feb 2026 9:51AM |
$3.600 |
$2.900 |
fallen by
19.44%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$386 |
FY25 Results Investor Presentation
|
27 Feb 2026 9:51AM |
$1.235 |
$1.310 |
risen by
6.07%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Return on Equity increased to 17.4%.
- Total capital ratio at 17.1%, above regulatory threshold.
- Cost to Income Ratio improved to 54.7%.
- Final dividend increased by 22% to 19.3 toea.
- Earnings per share grew by 20% to 41.8 toea.
- Revenue rose by 13% to K545.5 million.
- Lending income increased by 22%.
- Loan book growth of 13%.
- Net interest margin improved with higher Treasury Bill yields.
- Non-interest revenue driven by FX and digital income.
- Operational costs increased by 4% due to strategic investments.
- Improvement in asset quality and capital adequacy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Swift TV Limited (STV) ORDINARY FULLY PAID |
Communication Services |
$10 |
Half Year Accounts and Appendix 4D
|
27 Feb 2026 9:51AM |
$0.011 |
$0.009 |
fallen by
18.18%
|
|
STV - Price-sensitive ASX Announcement
Full Release
Key Points
- Swift TV Limited reported a comprehensive loss of $536,000 for the half year.
- 86.2% of revenues were recurring, aiding financial stability amid reduced expenses.
- Cash position decreased to $1,780,000 due to investments in Swift TV development.
- Pre-orders for Swift TV devices reached over 4,300, with commercial release on track for Q3 2026.
- No dividends were declared during the reporting period.
- Strategic investment continues in sales, marketing, and product development for market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strata Minerals Limited (SMX) ORDINARY FULLY PAID |
Materials |
$8 |
Application for quotation of securities - SMX
|
27 Feb 2026 9:50AM |
$0.022 |
$0.019 |
fallen by
13.64%
|
|
| Ainsworth Game Technology Limited (AGI) ORDINARY FULLY PAID |
Consumer Discretionary |
$472 |
CY25 Full Year Financial Results Investor Presentation
|
27 Feb 2026 9:50AM |
$1.050 |
$1.400 |
risen by
33.33%
|
|
AGI - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 10% compared to the previous corresponding period (PCP).
- Gross margin impacted by product sales mix in the Americas and tariff introductions in North America.
- Underlying EBITDA of $48.0 million was consistent with the PCP, but margins compressed to 16.5%.
- Gaming operations units totaled 6,091, a reduction from the previous year.
- Net debt position of $11.8 million at year-end, compared to a net cash position of $9.7 million the previous year.
- No dividends were paid to maintain liquidity and invest in product developments.
- The A-Star Raptor dual screen cabinet performed well in the APAC region.
- A $43.1 million goodwill impairment was recognized in North America.
- Income tax benefit of $25.2 million was recorded, driven by deferred tax asset recognition.
- The A-Star Raptor cabinet launched with strong market traction, with 1,829 units sold.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ardea Resources Limited (ARL) ORDINARY FULLY PAID |
Materials |
$140 |
Trading Halt
|
27 Feb 2026 9:50AM |
$0.680 |
$0.635 |
fallen by
6.62%
|
|
ARL - Price-sensitive ASX Announcement
Full Release
Key Points
- Ardea Resources Limited (ASX: ARL) requested a trading halt.
- The trading halt is pending the release of an announcement related to an equity raising.
- The trading halt is effective until the start of normal trading on 3 March 2026, or until the company releases the announcement.
- ASX Compliance issued the trading halt.
- Ardea Resources Limited's business office is located in West Perth, Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Maggie Beer Holdings Ltd (MBH) ORDINARY FULLY PAID |
Consumer Staple |
$36 |
1HFY26 Results Announcement
|
27 Feb 2026 9:49AM |
$0.081 |
$0.080 |
fallen by
1.23%
|
|
MBH - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Profit After Tax from continued operations increased by 68% to $398,000.
- Maggie Beer Products division sales increased by 4.6% due to focus on key sales channels.
- Operational and other savings of $2.2 million contributed to a total improvement of $3.4 million over the last 12 months.
- Strong balance sheet with $15.5 million in available liquidity, no debt, and $11.5 million in improved cash position.
- Hampers and Gifts Australia business remained profitable despite challenging market conditions.
- Unsolicited and non-binding offers received for the HGA business, under evaluation for potential business changes.
- Focus on improving gross margins and sales in key export markets for Maggie Beer Products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$115 |
Lumos Delivers Several Pivotal Milestones in 1H FY26
|
27 Feb 2026 9:49AM |
$0.255 |
$0.125 |
fallen by
50.98%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Secured US$317 million exclusive distribution agreement with PHASE Scientific.
- Completed FebriDx® CLIA waiver clinical study and FDA submission.
- Achieved full Medicare reimbursement recognition across U.S. MAC jurisdictions.
- Positive operating cash flow of $0.8 million, improving by $7.1 million over the prior period.
- Received US$2.75 million in non-dilutive grant funding.
- Initiated BARDA-funded CLIA waived paediatric study.
- Focused on securing FDA CLIA waiver for FebriDx® by the end of Q1 CY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Environmental Clean Technologies Limited (ECT) ORDINARY FULLY PAID |
Industrials |
$52 |
Notification of buy-back - ECT
|
27 Feb 2026 9:49AM |
$0.130 |
$0.125 |
fallen by
3.85%
|
|
| Maggie Beer Holdings Ltd (MBH) ORDINARY FULLY PAID |
Consumer Staple |
$36 |
Half Yearly Report and Accounts
|
27 Feb 2026 9:49AM |
$0.081 |
$0.080 |
fallen by
1.23%
|
|
MBH - Price-sensitive ASX Announcement
Full Release
Key Points
- Maggie Beer Holdings Ltd reported a net profit of $0.4 million from continuing operations for the half-year ended 31 December 2025.
- The group experienced a slight revenue decline of 1.7% to $52.9 million compared to the previous corresponding period.
- Maggie Beer Products (MBP) saw a revenue growth of 4.6% with new product launches and increased sales across most retail customers.
- Hampers and Gifts Australia (HGA) faced challenges with a 4.8% revenue decline, impacted by competitive markets and website issues.
- Gross margin for the group remained flat at 50.0%, while HGA improved its gross margin to 56.5% due to reduced discounting.
- A strategic review of HGA was initiated following unsolicited approaches from external parties.
- The company raised $2.98 million through a share placement and an additional $2.3 million via a rights issue.
- The balance sheet remained strong with net assets of $39.0 million and a net cash position of $12.6 million as of 31 December 2025.
- No dividends were declared or paid during the financial period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ainsworth Game Technology Limited (AGI) ORDINARY FULLY PAID |
Consumer Discretionary |
$472 |
CY25 Full Year Financial Results 31.12.25
|
27 Feb 2026 9:49AM |
$1.050 |
$1.400 |
risen by
33.33%
|
|
AGI - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit Before Tax of $21.1 million for CY25.
- Revenue increased by 10% to $290.8 million.
- Underlying EBITDA of $48.0 million.
- EBITDA margin decreased by 1.8%.
- International revenues accounted for 80% of total revenue.
- North America's revenue was $151.3 million.
- Asia Pacific revenue increased by 52%.
- Latin America/Europe revenue increased to $69.3 million.
- Online segment revenue decreased to $5.2 million.
- Non-cash impairment of $43.1 million recorded.
- Operating costs rose by 5.6%.
- Research & Development expenses increased by 1%.
- Operating cash outflows of $3.7 million.
- Increased borrowings resulted in a Debt/Equity ratio of 28%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Avenira Limited (AEV) ORDINARY FULLY PAID |
Materials |
$34 |
Proposed issue of securities - AEV
|
27 Feb 2026 9:48AM |
$0.008 |
$0.008 |
fallen by
0%
|
|
| Ainsworth Game Technology Limited (AGI) ORDINARY FULLY PAID |
Consumer Discretionary |
$472 |
App4E & Annual Financial Report for Year Ended 31.12.25
|
27 Feb 2026 9:48AM |
$1.050 |
$1.400 |
risen by
33.33%
|
|
AGI - Price-sensitive ASX Announcement
Full Release
Key Points
- Ainsworth Game Technology Limited reported revenue of AUD 290.8 million for 2025.
- The company faced a net loss of AUD 19.2 million during this period.
- Revenue from North America, the largest market, decreased in contribution percentage.
- Online revenue fell due to the end of the exclusivity agreement with GAN.
- No dividends were declared for the year ended 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID |
Health Care |
$1,080 |
Half Yearly Report and Accounts
|
27 Feb 2026 9:48AM |
$3.600 |
$2.900 |
fallen by
19.44%
|
|
CU6 - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant increase in losses from ordinary activities after tax.
- Net tangible assets per ordinary security increased to 62.6 cents.
- No dividends declared during the period.
- Winding up of Clarity Pharmaceuticals Europe SA.
- Financial statements reviewed by Grant Thornton with an unmodified opinion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$18 |
Notice under Section 708A(5)(e) of the Corps Act
|
27 Feb 2026 9:48AM |
$0.065 |
$0.060 |
fallen by
7.69%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$18 |
Application for quotation of securities - NOX
|
27 Feb 2026 9:47AM |
$0.065 |
$0.060 |
fallen by
7.69%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$115 |
Appendix 4D and Half Year Report
|
27 Feb 2026 9:47AM |
$0.255 |
$0.125 |
fallen by
50.98%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss increased to US$4.88 million.
- Revenues decreased by 2.9% to US$6.12 million.
- All revenues generated in the United States.
- Adjusted EBITDA loss increased due to investments.
- No dividends declared during the period.
- New loan facility for working capital introduced.
- 22 million performance rights granted to CEO.
- Directors believe the company will remain a going concern.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alara Resources Limited (AUQ) ORDINARY FULLY PAID |
Materials |
$25 |
Change of Company Secretary and Registered Address
|
27 Feb 2026 9:47AM |
$0.034 |
$0.032 |
fallen by
7.35%
|
|
| Joyce Corporation Limited (JYC) ORDINARY FULLY PAID |
Consumer Discretionary |
$172 |
Dividend/Distribution - JYC
|
27 Feb 2026 9:47AM |
$5.270 |
$5.820 |
risen by
10.44%
|
|
| Swoop Holdings Limited (SWP) ORDINARY FULLY PAID |
Communication Services |
$37 |
Correction to H1FY26 Investor Briefing Announcement
|
27 Feb 2026 9:46AM |
$0.140 |
$0.120 |
fallen by
14.29%
|
|
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$969 |
Corporate Governance Statement and Appendix 4G
|
27 Feb 2026 9:46AM |
$8.870 |
$9.950 |
risen by
12.18%
|
|
| SRJ Technologies Group plc (SRJ) CHESS DEPOSITARY INTERESTS 1:1 |
Energy |
$15 |
Preliminary Final Report
|
27 Feb 2026 9:46AM |
$0.011 |
$0.011 |
fallen by
4.55%
|
|
SRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Comprehensive loss of £3,519,269 for the year ended 31 December 2025.
- Significant issuance of new shares, impacting share capital.
- Acquisition of First Avenue General Contracting LLC for strategic regional opportunities.
- Financial adjustments and impacts from amortisation and foreign exchange.
- Detailed cash flow management including financing activities.
- Active management of tangible and intangible asset investments.
- Ongoing lease agreements and related party transactions.
- Focus on Middle East strategic opportunities post-acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$49 |
Appendix 4G and Corporate Governance Statement
|
27 Feb 2026 9:46AM |
$0.036 |
$0.042 |
risen by
16.67%
|
|
Call 1300 880 160
Start a chat
Schedule a call
